NASDAQ:LAB Standard BioTools Q4 2025 Earnings Results & Report $0.69 +0.02 (+2.85%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.71 +0.02 (+3.57%) As of 10/9/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Standard BioTools beat analyst expectations on both earnings and revenue in its Q4 2025 results, released February 24, 2026. The company reported EPS of $0.05 versus the -$0.03 consensus estimate, while revenue of $23.80 million topped the $18.50 million estimate by $5.30 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 24, 2026TimeAfter Market ClosesConference Call4:00 PM ET Standard BioTools EPS ResultsActual EPS$0.05Consensus EPS -$0.03Beat/MissBeat by +$0.08One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersStandard BioTools Revenue ResultsActual Revenue$23.80 millionExpected Revenue$18.50 millionBeat/MissBeat by +$5.30 millionYoY Revenue GrowthN/AUpcoming EarningsStandard BioTools' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Standard BioTools Q4 2025 Earnings FAQ Did Standard BioTools beat earnings estimates for Q4 2025? Standard BioTools (NASDAQ:LAB) reported earnings of $0.05 per share for Q4 2025, beating the consensus estimate of -$0.03. The report was announced on Tuesday, February 24, 2026. What was Standard BioTools' revenue for Q4 2025? Standard BioTools reported revenue of $23.80 million for Q4 2025, against a consensus estimate of $18.50 million. When is Standard BioTools' next earnings date? Standard BioTools' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Standard BioTools on the company's earnings history page. Standard BioTools Earnings HeadlinesStandard Biotools Agrees To Sell Microfluidics Business To ARCHIMEDOctober 5, 2026 | rttnews.comStandard BioTools to sell microfluidics business to ARCHIMEDOctober 5, 2026 | msn.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 10 at 1:00 AM | Behind the Markets (Ad)Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMEDOctober 5, 2026 | globenewswire.comStandard BioTools consensus price target lowered by 12.90% to $1.38October 2, 2026 | msn.comStandard BioTools Inc.: Standard BioTools Provides Update on Sale of Mass Cytometry BusinessOctober 1, 2026 | finanznachrichten.deSee More Standard BioTools Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Standard BioTools? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Standard BioTools and other key companies, straight to your email. Email Address About Standard BioToolsStandard BioTools (NASDAQ:LAB) (NASDAQ:LAB) develops and supplies technologies, instruments and consumables used in biomedical research. Its products are designed to help researchers analyze cells, proteins, genes and other biological systems, supporting applications in immunology, oncology, drug discovery and precision medicine. The company’s offerings include mass cytometry systems, which measure numerous cellular markers simultaneously; imaging mass cytometry platforms for analyzing biomarkers within tissue samples; and microfluidic tools for genomic and single-cell analysis. Following its combination with SomaLogic, Standard BioTools also offers the SomaScan proteomics platform, which enables high-throughput measurement of thousands of proteins in biological samples. Standard BioTools was formerly known as Fluidigm Corporation and adopted its current name in 2022. The company serves academic and government research institutions, pharmaceutical and biotechnology companies, and clinical research organizations internationally. Its corporate headquarters are in South San Francisco, California, and Michael Egholm serves as chief executive officer.View Standard BioTools ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
